"In the Spotlight: LinXis technology discussed in Dutch medical oncology journal"Read more
Breast cancer hits millions of women worldwide every year.
In many of these cases, the cancer cells express a particular trait called Her2. This molecule plays a role in growth of the cancer. More importantly however, the Her2 molecule represents an excellent target for therapy. Smart medicines targeted against the Her2 molecule hold great promise for treating breast cancer, particularly in cases that resist surgery and are hard to treat.
We have designed and developed an antibody-drug conjugate that targets the Her2 molecules present on cancer cells. It consists of the Her2 targeting antibody trastuzumab and is equipped with the super-potent drug Auristatin F by means of our Lx® Linker. We termed this product LxC-001, and in several laboratory studies, we showed that it was markedly more effective than current treatments, and well tolerated at the same time.